Gyre Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results showed a top-line beat with revenue of $29.1M exceeding the $26.5M consensus by 9.9%. However, profitability significantly missed expectations, with a GAAP EPS of -$0.12 vs. the -$0.06 expected, and a normalized net loss of $12.2M compared to an anticipated profit of $1.9M. The variance was primarily driven by a 129% YoY surge in R&D expenses, including a $4.8M milestone payment for the F351 NDA acceptance, alongside $0.5M in transaction costs from the Cullgen acquisition. Management affirmed full-year revenue guidance of $100.5M–$111.0M, supporting a steady commercial outlook despite the earnings miss.